Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

Patients with progressive pulmonary fibrosis, identified at any of nine participating leading U.S. medical centers, will be randomized (by computer) in a 1:1 ratio to either AART or treatment as usual (TAU). Stratification factors for randomization are sex (self-identified) and whether or not patients are taking any IPF-approved medication. Patients will be observed for six (6) months, with observations and assessments made at baseline, 30 days after randomization, and 90 and 180 days after randomization. Data will be electronically submitted via electronic case report forms (eCRF) to a Data Coordinating Center. The University of Alabama Medical Center Institutional Review Board (IRB) will be the central IRB for all sites. Specimens collected will also be used in experimental B-cell studies conducted in the laboratory of the Principal Investigator.